Sigma Planning Corp Fibrogen Inc Transaction History

Sigma Planning Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	BUY	$2.49 - $20.59 $54,817 - $453,288	22,015 Added 88.29%	46,950 $126,000
Q1 2023 May 05, 2023	SELL	$15.95 - $25.18 $47,371 - $74,784	-2,970 Reduced 10.64%	24,935 $465,000
Q3 2022 Nov 10, 2022	BUY	$11.4 - $14.6 $47,082 - $60,298	4,130 Added 17.37%	27,905 $363,000
Q2 2022 Aug 11, 2022	BUY	$7.94 - $12.96 $8,337 - $13,608	1,050 Added 4.62%	23,775 $251,000
Q1 2022 Apr 20, 2022	BUY	$12.02 - $16.79 $50,484 - $70,518	4,200 Added 22.67%	22,725 $273,000
Q4 2021 Feb 02, 2022	SELL	$9.93 - $15.39 $993 - $1,539	-100 Reduced 0.54%	18,525 $261,000
Q3 2021 Oct 28, 2021	BUY	$10.18 - $26.64 $189,602 - $496,170	18,625 New	18,625 $190,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.